- Sarepta crashes into an unexpected hurdle for its gene therapyInvestor’s Business Daily
- Sarepta comes across doubts about drug approval. Buy the stock, analysts say.Barrons
- U-turn, FDA orders AdComm for Sarepta’s DMD gene therapyFierceBiotech
- Sarepta Therapeutics Announces Advisory Board Meeting for SRP-9001Yahoo finance
- FAIRNESS ALERT: ROSEN, A TOP-TIER LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors Should Aware of Securities Class Action Investigation – SRPTbusiness thread
- See full coverage on Google News